TICKERNERD
Menu
CVSCVSHealthcare · Healthcare Plans

CVS Stock Forecast: CVS Health Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$89
−1.58% on the day

The 27 Wall Street analysts covering CVS Health Corp. hold a median 12-month price target of $116 — +30.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$113.6B
Ticker Nerd rank
88 / 100
Median analyst target
$116
Analysts covering
27
Revenue$106.1B+7.3% y/y
Operating income$4.7B
Net income$3.0B
Free cash flow$5.7B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.1%
1M
−6.4%
YTD
+14.5%
1Y
+23.1%
From 52W high
−19.2%
From 52W low
+28.7%
$69
$110
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CVS Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
88 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
95
Revisions
85
Issuance
85
Momentum
82
Growth
78
Value
77
Accruals
74
Quality
27
Size
2

Volatility (95): The share price has been relatively steady.

Quality (27): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26CVSHigh $148Median $116Low $103

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says27 analysts
24 Buy3 Hold0 Sell
Low $103Median $116High $148

The green dot is the last close — the median target sits +30.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
3 Sept 2026UBSMaintainsBuy$126 → $118
19 Aug 2026Argus ResearchMaintainsBuy$104 → $114
19 Aug 2026Argus ResearchMaintainsBuy—
12 Aug 2026JP MorganMaintainsOverweight$111 → $118
12 Aug 2026JP MorganMaintainsOverweight—
6 Aug 2026BarclaysMaintainsOverweight—
6 Aug 2026BarclaysMaintainsOverweight$106 → $108
6 Aug 2026Evercore ISI GroupMaintainsOutperform$130 → $125
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026UBSMaintainsBuy$122 → $126
6 Aug 2026UBSMaintainsBuy—
25 July 2026UBSMaintainsBuy—
24 July 2026UBSMaintainsBuy$115 → $122
14 July 2026Truist SecuritiesMaintainsBuy—
14 July 2026Truist SecuritiesMaintainsBuy$108 → $118
13 July 2026Wells FargoMaintainsOverweight—
13 July 2026Wells FargoMaintainsOverweight$103 → $123
9 July 2026RBC CapitalMaintainsOutperform—
9 July 2026RBC CapitalMaintainsOutperform$107 → $113
7 July 2026Cantor FitzgeraldMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CVS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, CVS Health Corp. returned +23.1% against +16.3% for the S&P 500, dividends included.

CVS vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Oct 25Jan 26Apr 26Jul 26CVSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+8.0%
Analysts raising
23
Analysts cutting
0
Fundamentals

CVS Health Corp. (CVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.4×

Cheaper than 32% of US stocks

Price / sales
0.3×

Cheaper than 90% of US stocks

Price / book
1.4×

Cheaper than 57% of US stocks

EV / EBITDA
10.6×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
7.1%

Higher than 44% of US stocks

Earnings growth (YoY)
191.8%

Higher than 90% of US stocks

Gross margin
14.8%

Higher than 14% of US stocks

Operating margin
3.9%

Higher than 52% of US stocks

Net margin
1.2%

Higher than 50% of US stocks

Returns & dividend
Return on equity
6.2%

Higher than 55% of US stocks

Return on assets
3.0%

Higher than 65% of US stocks

Dividend yield
3.0%

Higher than 63% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CVS Health Corp. (CVS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CVS Health Corp. has a market value of $113.6B and an enterprise value of $176.2B.

  • Revenue in the twelve months to 30 June 2026: $415.1B. The latest quarter grew 7.1% year on year.

  • Net income over the same four quarters: $4.9B, a 1.2% net margin.

  • Diluted earnings per share, trailing twelve months: $3.78.

  • Free cash flow in the twelve months to 30 June 2026: $11.8B.

  • CVS Health Corp. spent $3.4B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.3B.

  • Trailing P/E: 23.4×; forward P/E: 10.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.99%, paying out 70% of earnings.

  • CVS Health Corp. employs 219,000 people — $1.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

CVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
CVSCVS Health Corp.$113.6B
88
ELVElevance Health, Inc.$91.3B
68
CIThe Cigna Group$72.7B
69
HUMHumana, Inc.$46.5B
43
UNHUnitedHealth Group, Inc.$341.4B
77
CNCCentene Corp.$32.0B
95
MOHMolina Healthcare, Inc.$10.3B
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CVS Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CVS news & analysis

CVS Health's Aetna to streamline cancer treatment approvals

Reuters · 17 Sept 2026positive

CVS Health's Aetna insurance unit said it will cut back next year on the preapprovals it requires for cancer patient treatment, reducing them to only one medical prior authorization process early on. The company made the announcement on Thursday.

Why it matters — CVS watchers would care because this change affects how Aetna, a key segment of CVS Health's operations, administers cancer care coverage and prior authorizations.

Aetna expands bundled oncology prior authorizations, easing provider burden and accelerating member access to care

PRNewsWire · 17 Sept 2026positive

Aetna, a CVS Health company, has expanded prior authorization bundles to cover all cancer types for eligible Medicaid members as of September 1, with plans to roll the program out across all its lines of business by 2027. The change is intended to ease the burden on providers and speed member access to care.

Why it matters — CVS watchers would care because the expansion of Aetna's oncology prior-authorization bundling could affect provider relationships and member access across a growing portion of the health-services business.

CVS Trading Well Below Wall Street Targets After Month's Softening Creates Opening

24/7 Wall Street · 16 Sept 2026neutral

CVS shares are trading well below Wall Street price targets after a month of softening in the stock. The article notes the stock trades at a cheap forward multiple and that analysts are already bullish, but it also flags risks that could turn the setup into a trap.

Why it matters — A CVS watcher would want to assess whether the stock's discounted valuation and analyst optimism offset the cautionary risks highlighted in the piece.

CVS Health (CVS) Suffers a Larger Drop Than the General Market: Key Insights

Zacks Investment Research · 15 Sept 2026negative

CVS Health's stock closed the recent trading session at $94.43, down 1.17% from its prior day's close, a larger decline than that of the general market.

Why it matters — The decline shows CVS shares underperformed the broader market during the session, which is relevant for investors tracking the stock's relative momentum.

Here's How CVS' Health Services Arm Is Positioned for Long-Term Growth

Zacks Investment Research · 15 Sept 2026positive

CVS Health's Health Services segment is positioned for long-term growth, supported by pharmacy strength and improved care delivery. Robust new sales and strong clinic economics are contributing to the segment's expansion.

Why it matters — CVS watchers would care because growth in the Health Services arm, driven by pharmacy performance and care delivery improvements, is a key component of the company's overall long-term strategy.

FAQ

Frequently asked questions about CVS stock

What is the CVS stock price forecast for 2026-2027?

The 27 Wall Street analysts covering CVS Health Corp. have a median 12-month price target of $116, with estimates ranging from $103 to $148. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVS stock a buy right now?

Of the 27 analysts covering CVS Health Corp., 24 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CVS Health Corp. 88 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVS?

As at 19 Sept 2026, CVS Health Corp. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).

Will CVS stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +30.6% from the last close, and Ticker Nerd's factor model ranks CVS Health Corp. 88 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVS stock forecast for 2030?

No analyst covering CVS Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $148 over the next 12 months.

How has CVS stock performed over the past year?

CVS Health Corp. returned +23.1% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CVS Health Corp. do?

CVS Health Corporation Common Stock represents ownership in CVS Health Corporation, a U.S. health solutions company headquartered in Woonsocket, Rhode Island.

What is the latest news on CVS?

The most recent item we track (Reuters, 17 Sept 2026): "CVS Health's Aetna to streamline cancer treatment approvals". CVS Health's Aetna insurance unit said it will cut back next year on the preapprovals it requires for cancer patient treatment, reducing them to only one medical prior authorization process early on. The company made the announcement on Thursday.

Company

About CVS Health Corp.

CVS Health Corporation Common Stock represents ownership in CVS Health Corporation, a U.S. health solutions company headquartered in Woonsocket, Rhode Island. The company operates across health care benefits, health services, pharmacy, and consumer wellness, serving members, patients, employers, health plans, and public-sector clients. Its businesses include health insurance and managed care services, pharmacy benefit management, retail and specialty pharmacy operations, and a broad range of consumer-facing health and wellness services. CVS Health also supports medication access, clinical care, and coordinated care delivery through integrated offerings that connect insurers, pharmacies, and care services. As a large diversified health care enterprise, CVS Health plays an important role in the U.S. health system by linking coverage, pharmacy services, and patient care in one integrated platform.

CEO Mr. J. David Joyner CEBS · 219,000 employees · United States · https://www.cvshealth.com